Market Research Logo

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Pipeline Review, H2 2018

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Pipeline Review, H2 2018

Summary

Introduction
Global Markets Direct Report Coverage
Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Overview
Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Companies Involved in Therapeutics Development
GlaxoSmithKline Plc
Kyorin Pharmaceutical Co Ltd
Shire Plc
Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Drug Profiles
BaxB-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BaxG-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibudilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INV-88 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
malaria vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MFC-1040 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MFC-2040 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MIF-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibits MIF for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-425 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit MIF for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Macrophage Migration Inhibitory Factor for Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Dormant Products
Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Discontinued Products
Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Product Development Milestones
Featured News & Press Releases
Aug 31, 2018: MediciNova reports positive results from SPRINT-MS trial
Aug 31, 2018: Multiple sclerosis drug slows brain shrinkage in NIH-funded trial
Aug 22, 2018: MediciNova to receive NIAAA funding for Phase llb trial of MN-166
Aug 08, 2018: MediciNova to start Phase ll/lll trial of MN-166 for DCM
Jul 31, 2018: MediciNova announces MN-166 (ibudilast) ALS abstract accepted for presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK
Jul 29, 2018: MediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial
Jul 13, 2018: Yale researchers identify target for novel malaria vaccine
Jul 09, 2018: MediciNova Announces Clinical Data from Subgroup Analyses of Completed Clinical Trial of MN-166 (ibudilast) in ALS
May 09, 2018: MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma
May 07, 2018: MediciNova Announces Plans to Collaborate with UCLA Researchers in Grant-Funded Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder and Withdrawal
Apr 26, 2018: MediciNova Announces Additional Data from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology 70th Annual Meeting
Apr 24, 2018: MediciNova Announces the Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting Plenary Session with Additional Imaging Data
Mar 29, 2018: MediciNova Announces Results of Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence
Feb 18, 2018: MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology 70th Annual Meeting
Feb 01, 2018: MediciNova Announces MN-166 (ibudilast) Demonstrated a 26% Reduction in Confirmed Disability Progression in the SPRINT-MS Phase 2b Trial in Progressive MS: Potential Best-in-Disease Drug
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by GlaxoSmithKline Plc, H2 2018
Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018
Pipeline by Shire Plc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report